Skip to main content

Table 1 Aldosterone blockers for LV hypertrophy in CKD

From: Cardiac hypertrophy in chronic kidney disease—role of Aldosterone and FGF23

  Authors Study duration LV mass index LV function Hyperkalemia vs placebo Ref
CKD
 DM nephropathy Sato A. et al. 24 weeks Decreased   (No change) [10]
 Stage 2~3 CKD Edwards NC et al. 40 weeks Decreased Improved No difference [45, 46]
Hemodialysis
  Feniman-De-Ste fano GM et al. 6 months Decreased No change No difference [47]
  Taheri S et al. 6 months Decreased Improved No difference [48]
  Lin C. et al. 2 years Decreased Improved No difference [49]
  Matsumoto Y et al. 3 years Reduced death from cardiovascular events 3 of 157 patients discontinued [53]
Peritoneal dialysis
  Ito Y. et al. 2 years Decreased Improved No difference [50]
  Taheri S. et al. 6 months   Improved No difference [51]
  Hausmann MJ et al. 10 months   Improved (No change) [52]